Lung cancer trial: could adding chemo to targeted therapy buy more time?

This study looks at people with advanced non-small cell lung cancer that has a specific EGFR gene change. After 3 weeks on the standard targeted drug osimertinib, those whose cancer still shows the gene change in their blood are randomly assigned to either keep taking osimertinib alone or add two chemotherapy drugs (carboplatin and pemetrexed). The goal is to see if the combination helps delay cancer growth longer. About 80 adults with good performance status are taking part.